Dexamethasone reduces serum level of IL-17 in Bleomycin-A5-induced rats model of pulmonary fibrosis

7Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Pulmonary fibrosis is a chronic progressive disease with limited therapeutic options and inflammatory cytokines play important roles in the pathogenesis of pulmonary fibrosis. Material and method: Here, we investigated the changes of TGF-β1, IL-8, and IL-17 in the serum of bleomycin-A5-induced rats model of pulmonary fibrosis. 120 healthy male Wistar rats were randomly divided into three groups, the control group (n = 30), the model group (n = 45) and the dexamethasone (DEX) group (n = 45). The rats of both model group and DEX group were injected with Bleomycin-A5 (5 mg/kg) through tracheofistulization to induce pulmonary fibrosis, while the rats of the control group were injected with equivalent physiological saline. After operation, DEX (4 mg/kg) was given to the DEX group rats intraperitoneally once a day. Equivalent saline was administered to rats of both the control group and the model group. Results: On the 1st, 14th, and 28th day after operation, pathological changes of the lung tissues, and the levels of serum IL-8, TGF-β1, and IL-17 were measured. The concentrations of serum TGF-β1, IL-8, and IL-17 were significantly increased after bleomycin-A5 treatment, especially on the 14th day (p

Cite

CITATION STYLE

APA

Wang, A., Wang, F., Yin, Y., Zhang, M., & Chen, P. (2018). Dexamethasone reduces serum level of IL-17 in Bleomycin-A5-induced rats model of pulmonary fibrosis. Artificial Cells, Nanomedicine and Biotechnology, 46(4), 783–787. https://doi.org/10.1080/21691401.2017.1339051

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free